<DOC>
	<DOCNO>NCT01466608</DOCNO>
	<brief_summary>The aim study investigate pharmacokinetics , lipid lower effect lipidomic profile 8-weeks rosuvastatin treatment OATP1B1 genotype hyperlipidemia patient .</brief_summary>
	<brief_title>Influence OATP1B1 BRCP Genotype Rosuvastatin PK , PD Lipidomics Hyperlipidemic Patients</brief_title>
	<detailed_description>Within 3 week prior first administration study drug , volunteer agree participation study write consent undergo screening , include physical examination clinical laboratory test etc , evaluate whether eligible participate study . Study drug administer 9 A.M. morning first drug administration day , blood collection evaluation pharmacokinetics , lipid profile , metabolomics urine collection metabolomic genetic analysis . Subjects take investigational product every morning 8 week . On day 2nd , 4th , 6 8th week , blood collection evaluation pharmacokinetics , lipid profile , metabolomics urine collection metabolomics conduct visit clinical trial center . On day 2nd , 4th 6th week , study drug take blood urine collection .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Adults age 35 55 year time screen Serum LDL cholesterol ( LDLC ) level â‰¤130 mg/dL Must reliable willing make available study period Must willing give blood sample genotyping A subject present clinical manifestation past medical history hepatic , renal , respiratory , neurologic , hematologic , oncologic , psychiatric , cardiovascular endocrine disease , except hyperlipidemia mild hypertension ( SBP &lt; 160 mmg , DBP &lt; 100 mmHg ) . Administration lipid lower agent within 2 week first study drug administration . A subject history gastrointestinal disease surgery ( except simple appendectomy repair hernia ) , could influence absorption study drug . A subject history drug abuse , positive urine drug screen test A subject take take medication influence lipid lowering effect metabolic profile study drug study period . ( Investigators judge washout period previously use medication administration study drug . ) A subject participate clinical trial within 3 month study drug administration . A subject judge ineligible participate study due abnormal clinical laboratory result reason investigator .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>OATP1B1</keyword>
	<keyword>Rosuvastatin</keyword>
	<keyword>lipidomics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>